- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Ezetimibe does not increase risk of new - onset diabetes : IMPROVE-IT substudy
USA: Statins have been linked to an increased risk of new - onset diabetes (NOD). However, there seemed no clarity on whether adding the nonstatin therapy ezetimibe to a statin would impact the NOD incidence.
Therefore, Nishant P. Shah, Duke University School of Medicine, Durham, NC, USA, and colleagues evaluated the risk of new‐onset diabetes with ezetimibe addition to simvastatin versus placebo added to simvastatin in IMPROVE‐IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
The findings of the study, published in the Journal of the American Heart Association, supported the safety and use of this medication as an adjunct to statins for further lowering of low‐density lipoprotein cholesterol (LDL cholesterol), which, combined with the PCSK9 inhibitor data and recent trials, could be important for national guidelines.
The analyses included patients without diabetes at baseline. New-onset diabetes was defined for the primary analysis as either initiating an antihyperglycemic medication or two consecutive blood glucose measurements of ≥126 mg/dL and was analyzed as a time‐to‐event outcome. Metabolic syndrome at randomization was defined as ≥3 of the criteria defined by the American Heart Association.
Patients were assessed for 30 days after randomization and then after every four months, with a minimum 2.5‐year and median 6‐year follow‐up. Of the 18 144 patients enrolled in IMPROVE‐IT, 8644 were excluded due to missing data (N=3360) or a history of diabetes (N=5284), leaving 9500 patients for the study population.
The authors reported the following findings:
- After randomization, 14.9% of patients met the criteria for NOD for an annualized incidence of approximately 2.7% per year.
- For those who developed NOD, there were no differences in baseline characteristics between those who received simvastatin/ezetimibe (n=720) and those who received simvastatin/placebo (n=694).
- Compared with patients who did not develop NOD (n=8086), those with NOD were more likely at baseline to have a higher body mass index (hazard ratio [HR], 1.27), higher systolic blood pressure (HR, 1.07), higher triglycerides (HR, 1.33), and ≥ three components of the metabolic syndrome (HR, 1.36).
- The groups had no significant differences between baseline medical therapies or low‐density lipoprotein cholesterol.
- Compared with the placebo/simvastatin arm, there was no difference in risk of NOD with the addition of ezetimibe to simvastatin (HR, 1.03).
- The addition of ezetimibe did not affect the risk of NOD in either statin‐naïve (not on a previous statin before trial qualifying event) or statin‐experienced (on a previous statin before trial qualifying event) patients (HR, 1.01 versus HR, 1.08, respectively).
- Furthermore, in an additional sensitivity analysis to assess the risk of NOD based on the presence of metabolic syndrome at baseline, the addition of ezetimibe did not affect risk in those with metabolic syndrome or in those without metabolic syndrome (HR, 1.06 versus HR, 0.98 respectively).
In the analysis of patients enrolled in IMPROVE‐IT, the researchers found no increase in NOD risk with ezetimibe's addition to statin therapy.
"Our data are consistent and supported by the findings from a recent trial that found a lower NOD risk with lower dose ezetimibe and rosuvastatin versus higher dose rosuvastatin," Dr Shah and colleagues wrote. "A similar lack of NOD has been seen with PCSK9 inhibitors."
"Given outcomes from IMPROVE‐IT, and the absence of any signal that ezetimibe increases NOD risk, our results support the use and safety of this medication as an adjunct to statins for further LDL cholesterol lowering, which, combined with recent trials and the PCSK9 inhibitor data, could be important for national guidelines," they concluded.
Reference:
Shah NP, McGuire DK, Cannon CP, Giugliano RP, Lokhnygina Y, Page CB, Tershakovec AM, Braunwald E, Blazing MA. Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT. J Am Heart Assoc. 2023 Jun 22:e029593. doi: 10.1161/JAHA.122.029593. Epub ahead of print. PMID: 37345760.
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751